idw – Informationsdienst Wissenschaft

Nachrichten, Termine, Experten

Grafik: idw-Logo
Science Video Project
idw-Abo

idw-News App:

AppStore

Google Play Store



Instance:
Share on: 
11/12/2007 15:59

Professor Thomas Tuschl Receives Max Delbrück Medal

Barbara Bachtler Presse- und Öffentlichkeitsarbeit
Max-Delbrück-Centrum für Molekulare Medizin (MDC) Berlin-Buch

    E m ba r g o e d until: Monday, November 12, 17:30 GMT, 11:30 US Eastern Time

    Professor Thomas Tuschl from Rockefeller University in New York, USA, was honoured in Berlin, Germany with the Max-Delbrück-Medal. The German chemist developed a technique which enables researchers to literally "turn off" specific genes. This technology is called RNA-Interference (RNAi) and is now used in research laboratories all over the world to silence genes in cell culture to elucidate their function. Researchers also hope to employ RNAi-technology to silence disease genes in order to treat eye diseases, neurological diseases, hereditary diseases, and cancer in the future. Professor Nikolaus Rajewsky from the Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch, Germany held the laudatory address.

    Ribonucleid acid (RNA), the chemical relative of DNA, carries the genetic information which enables the cell machinery to produce proteins, the building blocks of life. However, when RNA is double-stranded, cells act to cut it into small pieces which, in turn, stop proteins from being made. This process occurs in plants, animals, and humans to protect them from viral infections. It also serves to regulate genes.

    While a postdoctoral student at the Massachusetts Institute of Technology (MIT) in Cambridge, USA, Thomas Tuschl laid the groundwork that led to his later discovery at the Max Planck Institute for Biophysical Chemistry in Goettingen, Germany. He could show, that synthetic double-stranded RNA is also cut into small pieces when inserted into cells. These small pieces, made up of 20 to 23 nucleotides, interfere with the messenger RNA and, thus, silence genes.

    In 2001, Tuschl, then working at the Max Planck Institute for Biophysical Chemistry in Göttingen, Germany, was able to show that RNAi also exists in human cells and that it can also specifically silence human genes.

    Thomas Tuschl was born on June 1, 1966 in Altdorf near Nuerenberg, Germany. He studied chemistry in Regensburg and earned his PhD in 1995 at the Max-Planck Institute for Experimental Medicine in Göttingen. During the following four years, he was a postdoctoral student in the laboratory of Nobel laureate Phillip Sharp at the Massachusetts Institute of Technology (MIT) in Cambridge, USA, and also worked at the nearby Whitehead Institute for Biomedical Research.

    In 1999, he returned to Germany to become a research group leader at the Max Planck-Institute for Biophysical Chemistry. In 2003, he was offered a position as Associate Professor at Rockefeller University in New York, USA, where he continues to work. A few years later he also became Investigator of the Howard Hughes Medical Institute (HHMI). Together with Phillip Sharp and other researchers, he founded the biopharmaceutical company Alnylam in Cambridge, USA, in 2002, which aims at developing novel therapeutics based on RNAi.

    Thomas Tuschl has received many scientific awards in Germany and the USA, among them the Ernst-Schering-Prize in 2005 in Berlin, and in 2003 the Mayor's Award for Excellence in Science and Technology in New York, the Wiley Prize in the Biomedical Sciences, and the Newcomb Cleveland Prize of the American Association for the Advancement of Science.
    Awarded annually since 1992, the Max Delbrück Medal is presented to outstanding scientists on the occasion of the "Berlin Lectures on Molecular Medicine", which the MDC organizes together with other Berlin research institutions and the Bayer Health Care, Bayer Schering Pharma (formerly Ernst Schering Research Foundation). The first award recipient was Professor Günter Blobel, who later received the Nobel Prize in Medicine.

    Barbara Bachtler
    Press and Public Affairs
    Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch
    Robert-Rössle-Straße 10; 13125 Berlin; Germany
    Phone: +49 (0) 30 94 06 - 38 96
    Fax: +49 (0) 30 94 06 - 38 33
    e-mail: presse@mdc-berlin.de
    http://www.mdc-berlin.de/englisch/about_the_mdc/public_relations/e_index.htm


    More information:

    http://www.rockefeller.edu/labheads/tuschl/
    http://en.wikipedia.org/wiki/Small_interfering_RNA
    http://en.wikipedia.org/wiki/Alnylam_Pharmaceuticals
    http://www.alnylam.com/


    Images

    Professor Thomas Tuschl, Rockefeller University New York, USA
    Professor Thomas Tuschl, Rockefeller University New York, USA
    (Photo: Clark Jones,AP/Copyright: HHMI)
    None


    Criteria of this press release:
    Biology, Chemistry, Information technology, Medicine, Nutrition / healthcare / nursing
    transregional, national
    Miscellaneous scientific news/publications, Personnel announcements
    English


     

    Professor Thomas Tuschl, Rockefeller University New York, USA


    For download

    x

    Help

    Search / advanced search of the idw archives
    Combination of search terms

    You can combine search terms with and, or and/or not, e.g. Philo not logy.

    Brackets

    You can use brackets to separate combinations from each other, e.g. (Philo not logy) or (Psycho and logy).

    Phrases

    Coherent groups of words will be located as complete phrases if you put them into quotation marks, e.g. “Federal Republic of Germany”.

    Selection criteria

    You can also use the advanced search without entering search terms. It will then follow the criteria you have selected (e.g. country or subject area).

    If you have not selected any criteria in a given category, the entire category will be searched (e.g. all subject areas or all countries).